Status:
COMPLETED
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Dysmenorrhea
Dyspareunia
Eligibility:
FEMALE
18-45 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pai...
Eligibility Criteria
Inclusion
- Surgical diagnosis of endometriosis within the last 10 years
- Sexually active, nonpregnant, nonlactating women (18-45 years) with regular menstrual cycles who are willing to use non-hormonal contraception
Exclusion
- Conditions requiring the use of chronic pain therapy
- Prophylactic use of analgesics to avoid endometriosis-related pain
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00318500
Start Date
May 1 2006
End Date
December 1 2006
Last Update
December 10 2007
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Montgomery, Alabama, United States, 36116
2
Chandler, Arizona, United States, 85225
3
Phoenix, Arizona, United States, 85032
4
Phoenix, Arizona, United States, 85035